Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Expanding access in pediatrics: Outcomes of haploidentical transplantation with reduced intensity and peripheral blood stem cells

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJulia E. Colunga‐PedrazaLVLaura Villarreal‐MartínezDGDavid Gómez‐Almaguer

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows cumulative incidence of graft-versus-host disease in pediatric patients undergoing haploidentical HSCT, indicating acceptable survival rates.

Key Points

  • To describe outcomes of pediatric patients undergoing haploidentical HSCT with reduced intensity conditioning and GVHD prophylaxis.
  • Retrospective study at a single center
  • Involved pediatric patients under 14 with hematological malignancies
  • Registry from January 2015 to April 2024
  • Patients received haploidentical HSCT with peripheral blood stem cells
  • Used post-transplant cyclophosphamide for GVHD prophylaxis
  • Forty-seven patients included, median age 8 years
  • Cumulative incidence of acute graft-versus-host disease grades II-IV at day 100 was 36%
  • Primary graft failure occurred in 4% of cases
  • Overall survival at one year was 79% and at two years was 68%
  • Event-free survival at two years was 63%

Cite This Study

Colunga‐Pedraza et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd01https://doi.org/10.1182/blood-2025-7714
View Full Paper
Ask AI
Bookmark
Share